Many proteins involved in protein-protein interactions are considered to be undruggable due to the large, flat binding surfaces involved in complex formation. Moreover, the current rules to obtain oral bioavailability and drug-like properties are not consistent with the type of molecules often needed to drug such challenging targets. This proposal outlines a plan to develop approaches for drugging proteins that are currently considered to be """"""""undruggable."""""""" The strategy will involve quickly eliminating proteins with little chance of being druggable from fragment-based screens and developing better computational approaches to accomplish this goal. Optimized fragment-based methods, structure-based design, and improved computational tools will be developed for lead identification and optimization. To obtain molecules with good oral bioavailability, the current rules concerning druglikeness will be challenged, and the importance of molecular size, flexibility, polar surface area, charge, and other parameters will be examined systematically. In addition, assays will be developed to identify the reasons for the lack of bioavailability to determine how to correct these deficiencies. By synthesizing and testing compounds (including control compounds) in multiple assays in a systematic fashion, the guidelines and approaches for drugging challenging targets will be established. This research could revolutionize our approach to drug discovery, lead to new drugs to better treat disease in all therapeutic areas, and thus have a dramatic impact on human health. Public Health Relevance: Of the 30,000 proteins in the human genome, only about 3,000 are thought to be druggable by small organic molecules;however, many of these undruggable proteins are highly validated and could serve as important targets in drug discovery providing suitable approaches are developed to drug these technically challenging targets. Expanding the druggable genome as outlined in this proposal could a

National Institute of Health (NIH)
Office of The Director, National Institutes of Health (OD)
NIH Director’s Pioneer Award (NDPA) (DP1)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-NDPA-B (01))
Program Officer
Jones, Warren
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Schools of Medicine
United States
Zip Code
Lee, Taekyu; Bian, Zhiguo; Zhao, Bin et al. (2017) Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett 591:240-251
Lee, Kyung-Min; Giltnane, Jennifer M; Balko, Justin M et al. (2017) MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab 26:633-647.e7
Pelz, Nicholas F; Bian, Zhiguo; Zhao, Bin et al. (2016) Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. J Med Chem 59:2054-66
Patrone, James D; Pelz, Nicholas F; Bates, Brittney S et al. (2016) Identification and Optimization of Anthranilic Acid Based Inhibitors of Replication Protein?A. ChemMedChem 11:893-9
Burke, Jason P; Bian, Zhiguo; Shaw, Subrata et al. (2015) Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design. J Med Chem 58:3794-805
Thomas, Lance R; Wang, Qingguo; Grieb, Brian C et al. (2015) Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Mol Cell 58:440-52
Harner, Mary J; Chauder, Brian A; Phan, Jason et al. (2014) Fragment-based screening of the bromodomain of ATAD2. J Med Chem 57:9687-92
Cox, Adrienne D; Fesik, Stephen W; Kimmelman, Alec C et al. (2014) Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov 13:828-51
Sun, Qi; Phan, Jason; Friberg, Anders R et al. (2014) A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand. J Biomol NMR 60:11-4
Burns, Michael C; Sun, Qi; Daniels, R Nathan et al. (2014) Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc Natl Acad Sci U S A 111:3401-6

Showing the most recent 10 out of 17 publications